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Introduction: Pathophysiologic changes associated with diabetes impair new blood vessel formation and wound
healing. Mesenchymal stem cells derived from adipose tissue (ASCs) have been used clinically to promote healing,
although it remains unclear whether diabetes impairs their functional and therapeutic capacity.
Methods: In this study, we examined the impact of diabetes on the murine ASC niche as well as on the potential
of isolated cells to promote neovascularization in vitro and in vivo. A novel single-cell analytical approach was used
to interrogate ASC heterogeneity and subpopulation dynamics in this pathologic setting.
Results: Our results demonstrate that diabetes alters the ASC niche in situ and that diabetic ASCs are compromised
in their ability to establish a vascular network both in vitro and in vivo. Moreover, these diabetic cells were
ineffective in promoting soft tissue neovascularization and wound healing. Single-cell transcriptional analysis
identified a subpopulation of cells which was diminished in both type 1 and type 2 models of diabetes. These cells
were characterized by the high expression of genes known to be important for new blood vessel growth.
Conclusions: Perturbations in specific cellular subpopulations, visible only on a single-cell level, represent a
previously unreported mechanism for the dysfunction of diabetic ASCs. These data suggest that the utility of
autologous ASCs for cell-based therapies in patients with diabetes may be limited and that interventions to improve
cell function before application are warranted.Introduction
Diabetes mellitus (DM) is associated with significant
impairments in neovascularization and wound healing
[1]. Although the exact mechanism underlying this path-
ology remains unknown, there is evidence for diabetes-
associated dysfunction at both the cellular and molecular
level. Specifically, diabetes has been linked to impairments
in the functionality of diabetic endothelial progenitor
cells (EPCs) and resident tissue fibroblast in vitro [2,3].
Additionally, reduced local expression of the vasculo-
genic and regenerative cytokines vascular endothelial* Correspondence: ggurtner@stanford.edu
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unless otherwise stated.cell growth factor (VEGF) and hypoxia-inducible factor
1-alpha (HIF-1α) has been reported in diabetic tissues
following injury [4,5].
A variety of treatment approaches that seek to address
the specific deficiencies present in diabetic wounds have
been developed. Cell-based therapies, in particular, repre-
sent an appealing treatment paradigm, as they potentially
contribute both cytokines and a cellular framework to
the tissue regeneration process. In support of this ap-
proach, multiple cell-based products delivering fibro-
blasts or fibroblast-keratinocyte mixtures have a proven
clinical efficacy for the treatment of diabetic wounds
[6]. Moreover, advanced biomaterials are being devel-
oped to optimize cell survival and functionality within
the harsh wound environment [7-9].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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an especially appealing therapeutic cell source because
of their multipotency, paracrine secretion of growth fac-
tors and cytokines [10], and demonstrated efficacy in
models of wound healing and ischemic revascularization
[11,12]. Additionally, adipose tissue presents a reservoir
of readily available cells, which can be easily harvested
and directly employed for autologous clinical application
[13]. This methodology obviates the need for ex vivo cell
expansion while avoiding the immunogenic concerns as-
sociated with allogeneic cell transplantation. The value
of autologous cell therapies in patients with diabetes
may be limited, however, as stem cell phenotypes can be
negatively impacted by diabetes [14,15], and diabetic
ASCs display an impaired neovascular potential in vitro
[16]. Nonetheless, the therapeutic efficacy of diabetic
ASCs within cutaneous wounds remains unclear [17].
Single-cell analytical approaches facilitate the in-depth
exploration of cell heterogeneity and subpopulation dy-
namics, and we have recently used this technique to
characterize stem cell phenotypes [18] and enhance ASC
functionality via predictive subpopulation enrichment
[19]. Importantly, determining the effect of diabetes on
ASCs with single-cell granularity is the only way to dif-
ferentiate between a global effect on cell functionality
and a more selective subpopulation-level influence. This
information is critically important for the design of effect-
ive autologous ASC-based therapies in patients with dia-
betes, as a global cell dysfunction would demand ex vivo
modulation prior to application, whereas subpopulation-
level effects may be overcome through more selective cell
enrichment. In this study, we examine the impact of
diabetes on the ASC niche as well as the ability of ASCs
to promote neovascularization and wound healing when
delivered within a biomimetic hydrogel scaffold devel-
oped in our laboratory [7,8]. Finally, we interrogate
these cells on a single-cell level to characterize ASC




Wild-type (WT) (C57BL/6) and type 2 diabetic (DM2)
mice (BKS.Cg-m +/+Leprdb) were purchased from
Jackson Laboratories (Bar Harbor, ME, USA) to study
the effect of diabetes on ASC physiology. Selected assays
were also performed on ASCs isolated from WT mice
following induction of type 1 diabetes (DM1) via strep-
tozotocin injection (STZ) (Sigma-Aldrich, St. Louis,
MO, USA) as previously described [20]. Only mice with
blood glucose levels of greater than 350 mg/dL were
considered diabetic and used for further analysis. All
protocols were approved by the Stanford Administrative
Panel on Laboratory Animal Care.ASC niche analysis
WT and DM2 murine inguinal fat pads were harvested
and manually disrupted for real-time quantitative poly-
merase chain reaction as described below.ASC harvest and culture
ASCs were isolated from WT, DM1, and DM2 murine in-
guinal fat pads, minced, and digested for 1 hour at 37°C
using collagenase I (Roche Applied Science, Indianapolis,
IN, USA). The reaction was stopped with the addition of
supplemented media, pelleted via centrifugation, and sub-
jected to erythrocyte lysis in accordance with the instruc-
tions of the manufacturer (Sigma-Aldrich). The remaining
cells were pelleted again, forming the stromal vascular
fraction (SVF). The SVF was either cultured under stand-
ard conditions (37°C in 5% CO2) in Dulbecco’s modified
Eagle’s medium (DMEM) with 10% fetal bovine serum
(FBS) and 1% penicillin/streptomycin (Life Technologies,
Grand Island, NY, USA) containing 1 g/L of glucose to
purify for ASCs or used immediately for flow cytometric/
single-cell analyses. Cultured cells were used at or before
passage 2, and all analyses were run in triplicate unless
otherwise stated.In vitro Matrigel tubulization assays
PKH26-labeled WT and DM2 ASCs alone or mixed with
calcein-labeled human umbilical vein endothelial cells
(HUVECs) (Life Technologies) were cultured for 12 hours
under hypoxic conditions on a 24-well plate (4 × 104 cells
per well) coated with growth factor-reduced Matrigel
(BD Biosciences, Franklin Lakes, NJ, USA). ASC and
HUVEC tubule counts were determined in five random
high-power fields per well, respectively, by using an
inverted Leica DMIL microscope (Leica Microsystems,
Wetzlar, Germany).In vivo Matrigel plug assay and CD31
immunohistochemistry
WT or DM2 ASCs (8 × 105) (cultured not more than two
passages) were suspended in 250 μL of growth factor-
reduced Matrigel (BD Biosciences) and injected in a sub-
cutaneous fashion on the dorsum of WT mice (n = 4).
Plugs were harvested at day 10, and 7-μm-thick frozen
sections were immunohistochemically stained for the
commonly used vascular marker platelet/endothelial cell
adhesion molecule 1 (PECAM1/CD31, a transmembrane
glycoprotein expressed on the surface of platelets, endo-
thelial cells, and subsets of hematopoietic cells but par-
ticularly concentrated at the intercellular junctions of
endothelial cells), followed by ImageJ (National Institutes
of Health, Bethesda, MD, USA) quantification [7,21].
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WT and DM2 ASCs were seeded in standard six-well tis-
sue culture plates (1.5 × 105 cells per well), and adipogenic
differentiation medium—consisting of DMEM (1 g/L glu-
cose), 10% fetal bovine serum, 1% penicillin/streptomycin,
10 μg/mL insulin, 1 μM dexamethasone, 0.5 mM methyl-
xanthine, and 200 μM indomethacin—was added after cell
attachment. Oil red O staining was performed after 7 days
of incubation.
In vitro osteogenic differentiation
WT and DM2 ASCs were seeded in standard six-well
tissue culture plates (1.0 × 105 cells per well) and grown
to at least 80% confluence before being cultured in
osteogenic differentiation medium, which consisted of
DMEM (1 g/L glucose) supplemented with 10% FBS, 1%
penicillin/streptomycin, 100 μg/mL ascorbic acid, and
10 mM β-glycerophosphate. Photometric quantification
of Alizarin red stain was performed after 14 days to assay
extracellular mineralization as previously described [22].
In vitro hydrogel bioscaffold seeding
WT and DM2 ASCs (1 × 105) were suspended in 15 μL
of growth media and seeded within a previously de-
scribed 5% collagen-pullulan hydrogel bioscaffold [7,8].
Seeded scaffolds were placed in growth media and incu-
bated at 37°C in 5% CO2 prior to proliferation and sur-
vival analyses and RNA/protein harvest.
In vitro proliferation and survival
After hydrogel bioscaffold seeding, a live-dead assay
(Live/Dead Cell Viability Assay) was performed at mul-
tiple time points to assess WT and DM2 ASC viability in
accordance with the instructions of the manufacturer
(Life Technologies). ASC proliferation was compared
between hydrogel-seeded WT and DM2 cells at mul-
tiple time points by using an MTT assay (Vybrant MTT
Cell Proliferation Assay Kit; Invitrogen, Grand Island,
NY, USA).
Real-time quantitative polymerase chain reaction
Total RNA was isolated from ground WT and DM2
fat pads or hydrogel-seeded ASCs by using an RNeasy
Mini Kit (Qiagen, Germantown, MD, USA) and tran-
scribed to cDNA (Superscript First-Strand Synthesis
Kit; Invitrogen). Real-time quantitative polymerase chain
reactions (qPCRs) were performed by using TaqMan gene
expression assays (Applied Biosystems, Foster City, CA,
USA) for murine Mmp-9 (matrix metalloproteinase 9,
Mm00442991_m1), Cxcl-12 (stromal cell-derived factor-
1/Sdf-1, Mm00445552_m1), Vegf-a (vascular endothe-
lial growth factor-A, Mm01281447_m1), Eng (endoglin,
Mm00468256_m1), Hgf (hepatocyte growth factor,
Mm01135193_m1), Mmp-3 (matrix metalloproteinase 3,Mm00440295_m1), Cxcr-4 (chemokine receptor 4,
Mm01292123_m1), Fgf-2 (fibroblast growth factor 2,
Mm00433287_m1), Fgfr-2 (fibroblast growth factor re-
ceptor 2, Mm01269930_m1), Pdgf-a (platelet-derived
growth factor-A, Mm01205760_m1), Pdfgr-a (platelet-
derived growth factor receptor-A, Mm01205760_m1),
and Angpt-1 (angiopoietin 1, Mm00456503_m1) by using
a Prism 7900HT Sequence Detection System (Applied
Biosystems). Expression levels of the target genes were
normalized to Actb (beta actin, Mm01205647_g1) or B2m
(beta-2-microglobulin, Mm00437764_m1).
Angiogenesis array
Angiogenic cytokine protein production from hydrogel-
seeded WT and DM2 ASCs was quantified by using a
Mouse Angiogenesis Array Kit (R&D Systems, Minneapolis,
MN, USA). Pixel density of each spot in the array was
quantified and normalized to controls by using ImageJ
(National Institutes of Health).
In vivo murine ischemia model
A model of graded soft tissue ischemia was created on
the dorsum of WT mice, as described previously [23].
Briefly, a full-thickness three-sided peninsular flap was
elevated, and a thin silicone sheet was inserted to separ-
ate the skin from the underlying fascia. A size-matched
hydrogel bioscaffold was inlaid between the silicon sheet
and skin flap either alone or following the seeding of
2.5 × 106 WT or diabetic (type 2 or 1) ASCs (cultured
not more than two passages) (n = 5). Unseeded scaffolds
were used as controls. The skin flap was then sutured
into place, and the demarcating necrotic area was
quantified 10 days post-op. The proximal surviving
flap was processed for neovascular growth via CD31
immunohistochemistry.
Microfluidic single-cell gene expression analysis
ASCs isolated from freshly harvested WT, DM2, and
DM1 SVF (obtained as described above) by using the
surface marker profile CD45−/CD31−/CD34+ (to exclude
contaminating CD45+ hematopoietic and CD31+ endo-
thelial cells found within the SVF and to select for a pu-
tatively stem-like subset of CD34+ cells [22,24]) were
analyzed and sorted as single cells by using a Becton
Dickinson FACSAria flow cytometer (Becton Dickinson,
Franklin Lakes, NJ, USA) into 6 μL of lysis buffer. Pro-
podium iodide exclusion was used to ensure that only
live cells were sorted. Reverse transcription and low
cycle pre-amplification were performed by using Cells
Direct (Invitrogen) with TaqMan assay primer sets (Ap-
plied Biosystems) in accordance with the specifications of
the manufacturers. cDNA was loaded onto 96.96 Dynamic
Arrays (Fluidigm, South San Francisco, CA, USA) for
qPCR amplification by using Universal PCR Master Mix
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assay primer set as previously described [18].
Statistical analysis
Results are presented as mean ± standard error of the
mean. Data analysis was performed by using a Student
t test. Results were considered significant for P values
of not more than 0.05. For single-cell transcriptional data,
a Kolmogorov-Smirnov (K-S) test was used to compare
empirical distributions, followed by an adaptive fuzzy c-
means clustering algorithm as previously described [18].Figure 1 Adipose-derived mesenchymal stem cell (ASC) niche charact
potential. (A) Transcriptional profile of type 2 diabetes mellitus (DM2) and
environment was observed in the setting of diabetes. (B) Matrigel culture o
high-power field (HPF) were quantified as a surrogate for direct ASC vascul
vein endothelial cells (HUVECs) under hypoxic conditions. HUVEC tubules p
network formation. (D) CD31 staining to quantify in vivo Matrigel plug vasc
gross images of explanted plugs. Scale bar = 50 μm. *P ≤0.05, **P <0.01.Results
Diabetes negatively impacts the ASC niche and impairs
ASC promotion of neovascularization
To determine the impact of diabetes on the ASC niche in
situ, the transcriptional profiles of DM2 and WT murine
fat pads were analyzed. Indicative of a dysfunctional sig-
naling environment in situ, the expression of multiple
growth factors and cytokines (Vegf-a, Fgf-2, Pdfg-a, and
Sdf-1; P <0.02) as well their associated receptors (Cxcr-4,
Fgfr-2, and Pdgfr-a; P <0.01) was significantly decreased in
the setting of diabetes (Figure 1A).erization and in vitro and in vivo analyses of ASC neovascular
wild-type (WT) murine fat pads. A dysfunctional in situ signaling
f WT and DM2 ASCs under hypoxic conditions. Tubules per
ogenic potential. (C) Matrigel co-culture of ASCs and human umbilical
er HPF were quantified as a measure of ASC-mediated endothelial
ularity following seeding with either WT or DM2 ASCs. Insets provide
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to support the generation of vascular structures, we con-
ducted a Matrigel tubule formation assay. When seeded
alone, DM2 ASCs displayed significantly fewer tubular
structures compared with WTcells (5.2 versus 30.6 tubules
per HPF, respectively; P <0.001) (Figure 1B), suggesting a
deficient response to extracellular matrix stimuli. ASCs are
known to mediate angiogenesis mainly through paracrine
mechanisms, however, as opposed to direct endothelial dif-
ferentiation [25]. To analyze the ability of ASCs to promote
endothelial sprouting, WT and DM2 ASCs were co-seeded
with HUVEC cells by using the same model. Interestingly,
although both ASC groups similarly localized around the
HUVECs, consistent with their perivascular nature, the
DM2 ASCs supported significantly less HUVEC tubule for-
mation compared with WTASCs (16.9 versus 27.1 tubules
per HPF; P = 0.001) (Figure 1C), indicating that diabetic
ASCs possess a reduced stimulatory capacity.Figure 2 Adipose-derived mesenchymal stem cell (ASC) adipogenic a
quantification of Oil red O and Alizarin red staining following adipogenic a
**P <0.01.To determine whether the observed in vitro findings
translated into impaired in vivo neovascularization, we
performed an assay in which Matrigel plugs seeded with
DM2 or WT ASCs were implanted into subcutaneous
pockets on the dorsum of WT mice, and new vessel for-
mation was histologically assessed after 10 days (a time
point at which neovascular processes are active following
injury [26]). Consistent with our in vitro findings, plugs
containing DM2 ASCs displayed significantly reduced
levels of vascularization (as determined by CD31 immuno-
histochemistry) compared with plugs seeded with WT
ASCs (0.38 versus 1.16% CD31 staining per HPF; P = 0.02)
(Figure 1D). Further exploring the effect of diabetes on
ASC stemness, DM2 ASCs also displayed impairments
in adipogenic and osteogenic differentiation in vitro
(Figure 2), consistent with a loss of cell stemness and a
phenotypic imprinting despite correction of the glucotic
environment. Together, these data demonstrate thatnd osteogenic differentiation. (A) Representative images and (B)
nd osteogenic differentiation of WT and DM2 ASCs. Scale bar = 50 μm.
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of ASCs to promote neovascularization both in vitro
and in vivo.
Optimization of ex vivo environment does not restore
diabetic ASC function
The delivery of cells to a wound site is particularly chal-
lenging because of a hostile environment characterized
by inflammation and poor nutritional support. We have
recently developed a biomimetic hydrogel scaffold, which
has been shown to support MSC survival, promote ‘stem-
like’ features, and improve pro-angiogenic functionality
[7,8]. To further characterize the effect of diabetes on the
angiogenic potential of ASCs and to determine whether
this function can be restored, we examined the cellular re-
sponse to seeding in this biomimetic hydrogel. Although
WT and DM2 ASCs displayed a similar seeding efficiency
and proliferation capacity within the hydrogel (Figure 3),
diabetic ASCs possessed a markedly abnormal morph-
ology (Figure 4A). Specifically, DM2 ASCs appeared to be
rounded and clumped and failed to form the cytoplasmic
extensions seen with WT cells, indicative of a lack of
cell interaction with the scaffold microenvironment. Im-
portantly, this phenotypic dysfunction in DM2 ASCs
was accompanied by a decrease in transcriptional expres-
sion and production of several vasculogenesis-related and
tissue remodeling mediators, including VEGF, MMP-9,
and HGF (P ≤0.03) (Figure 4B,C).
Diabetic ASCs fail to improve ischemic wound healing
in vivo
Diminished perfusion and neovascularization are import-
ant factors contributing to impaired diabetic healing; so to
evaluate the regenerative potential of diabetic ASCs under
representative conditions, cell-seeded biomimetic hydro-
gels were used in an adapted murine model of skin flap
ischemia (Figure 5A,B) [27]. Although the application of
WT ASCs showed a significant improvement in tissue
survival at day 10 as compared with controls (48.0%Figure 3 ASC behavior following in vitro hydrogel seeding. (A,B) Wild
proliferation and (B) survival in vitro following seeding within a three-dimeversus 22.3% flap survival; P = 0.02), flaps treated with
DM2 ASCs developed ischemic tissue necrosis at a level
similar to that of the cell-free controls (21.0% versus
22.3% flap survival; P = 0.87) (Figure 5C). This differ-
ence in tissue survival correlated with a deficiency of
DM2 ASCs in promoting new blood vessel formation
within the surviving proximal flap as compared to
WT ASCs (1.12% versus 2.34% CD31 staining per HPF;
P = 0.04) (Figure 5D,E). This time point is of particular
relevance as it is within the window of physiologic neovas-
cularization that occurs following injury but prior to vas-
cular regression that occurs as part of the normal tissue
remodeling process [26]. Moreover, these results were
recapitulated with ASCs isolated from streptozotocin-
induced (DM1) mice, indicating that the observed find-
ings were not model-specific, but rather reflect the im-
pact of prolonged hyperglycemia on ASC physiology
(Figure 5C-E). In aggregate, these data confirm the im-
paired vasculogenic potential of diabetic ASCs in vivo,
despite delivery within a biomimetic scaffold.Diabetes selectively depletes a subpopulation of ASCs
with a highly vasculogenic transcriptional profile
Because cell culture and/or surface marker based enrichment
of ASCs from the heterogeneous SVF is often employed
prior to application, understanding the effect of diabetes
on ASC population dynamics in the SVF, as well as follow-
ing purification, is critical. To first determine the influence
of diabetes on global ASC levels within the SVF, a flow
cytometric analysis was performed on WT, DM2, and
DM1 samples for the presence of putative ASCs (CD45−/
CD31−/CD34+ cells). Indicative of a detrimental effect of
diabetes on the global ASC population, both the DM2 and
DM1 SVF displayed a reduced frequency of putative ASCs
when compared with WT samples (P <0.01) (Figure 6).
Although this global ASC depletion provides an ex-
planation for the dysfunction of diabetic SVF, a finer de-
gree of granularity is needed to analyze purified ASCs
for phenotypic differences, especially as there is evidence-type (WT) and diabetic (DM2) ASCs display similar rates of (A)
nsional bioscaffold. ns, not significant (P >0.05).
Figure 4 Adipose-derived mesenchymal stem cell (ASC) incorporation and secretory function following hydrogel bioscaffold seeding.
(A) Wild-type (WT) and type 2 diabetes mellitus (DM2) ASCs at day 3 and 14 after hydrogel seeding. WT cells showed a uniform incorporation
within the hydrogel and developed cell elongations and cytoplasmic extensions indicative of interactions with the bioscaffold (gray arrowhead).
DM2 ASCs displayed a clumped distribution with rounded cell morphology (white arrowheads). (B) Reverse transcription-polymerase chain
reaction and protein array (C) quantifying the relative expression of selected genes associated with vasculogenenesis and tissue remodeling in
hydrogel-seeded WT versus DM2 ASCs. Scale bar = 50 μm. *P≤ 0.05, **P <0.01. Angpt-1, angiopoietin 1; Eng, endoglin; Hgf, hepatocyte growth factor;
Mmp-3, matrix metalloproteinase 3; Mmp-9, matrix metalloproteinase 9; Sdf-1, Stromal Cell-Derived Factor 1; Vegf, vascular endothelial cell growth factor.
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with varying levels of functionality [19]. To determine
the effect of diabetes on ASC subpopulation dynamics, a
single-cell interrogation of WT, DM2, and DM1 ASCs
was conducted. For this, we employed microfluidic-based
single-cell gene expression analysis as previously de-
scribed [18]. Transcriptional profiles were simultaneously
evaluated for approximately 70 gene targets across 75
individual cells per group, specifically looking at genes
relating to stemness, vasculogenesis, and tissue regener-
ation (Additional file 1: Table S1). These cells were pri-
mary ASCs isolated based on a primitive surface marker
definition (CD45−/CD31−/CD34+) intended to exclude
contaminating hematopoietic and endothelial cells found
within the SVF.When this approach was used, cells isolated from
both WT and diabetic mice were found to display sig-
nificant heterogeneity at the single-cell level (Figure 7A
and Additional file 2: Figure S1). Moreover, Kolmogorov-
Smirnov analysis of these single-cell data identified mul-
tiple genes that were differentially expressed in WT versus
type 2 or 1 diabetic ASCs, including genes related to tissue
remodeling, vasculogenesis, and cell differentiation, such
as the metalloproteinases Mmp-3 and Adam-10, the
chemokine Ccl-2, and the transcription factors Hif-1a
and Mef-2c (P <0.01) (Figure 7B) [28-32]. To determine
whether these differences were the result of changes in
specific subpopulations of diabetic or WT ASCs, parti-
tional clustering was applied to the super-set of tran-
scriptional profiles encompassing WT and diabetic cells
Figure 5 Hydrogel delivery of ASCs to promote ischemic tissue flap survival. (A) WT and DM (1 and 2) ASC-seeded hydrogels and
unseeded controls were inset following creation of a full-thickness peninsular skin flap, (B) resulting in the creation of a reproducible ischemic
gradient. (C) Tissue survival and vascularization as determined by (D) CD31 immunohistochemistry staining and (E) quantification were assessed
at day 10. Scale bar = 50 μm. *P ≤0.05.
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defined ASC subpopulations, which exhibited strikingly
different profiles across conditions (Figure 7C-E). Interest-
ingly, a distribution analysis of the cells comprising the
third cluster revealed that there were considerably fewer
diabetic ASCs compared with WT cells in this subpopu-
lation (Figure 7 F), with this cluster characterized in
part by the elevated expression of genes associated with
vasculogenesis, such as Angpt-1, Sdf-1, Mmp-3, and
Fzd-4 (Figure 7G) [29,33-35]. These data suggest that
this subpopulation may be primed to support vasculo-
genesis, and its depletion in the diabetic state provides a
potential mechanism for the impairment of diabetic
ASC vasculogenic potential.
Discussion
In this work, we provide a comprehensive analysis of the
reduced therapeutic potential of diabetic ASCs for the
promotion of tissue neovascularization and, for the first
time, identify the selective depletion of a subpopulation
of cells with a pro-vasculogenic phenotype in this set-
ting. One of the main clinical advantages of ASCs istheir ease of use in an autologous fashion. However, the
dysfunctional signaling environment observed in diabetic
fat pads suggests that prolonged hyperglycemia has multi-
dimensional detrimental effects on ASC niche homoeosta-
sis. Moreover, the continuous impairment of diabetic ASC
functionality following isolation and culture within an op-
timized biomimetic hydrogel scaffold significantly limits
the translational potential of autologously derived ASCs in
this population.
Supporting the irreversibility of these diabetes-related
impairments, the hydrogel scaffold used in this
work was created specifically to recapitulate the stem
cell niche and has been previously shown to enhance
the pro-vasculogenic cytokine secretion (VEGF,
MCP-1, FGF-1, MMPs, etc.) of bone marrow-derived
mesenchymal stem cells (BM-MSCs), improve BM-MSC
survival and engraftment within the high-oxidative-stress
environment of ischemic murine skin wounds, and ultim-
ately increase the angiogenic effect and wound-healing po-
tential of BM-MSC-based therapies [7,8]. Similarly, when
ASCs are seeded in this hydrogel, they display an upregu-
lation of vasculogenesis-related genes as well as an
Figure 6 Diabetic and wild-type (WT) stromal vascular fraction (SVF) cell surface marker analysis. (A) Flow cytometric analysis determining the
percentage of putative adipose-derived mesenchymal stem cells (ASCs) (CD45−/31−/34+ cells) within SVF obtained from diabetic (DM2 and DM1) and
WT mice (CD45 and live/dead gating not shown). (B) Quantification of CD45−/31−/34+ ASCs in WT, DM2, and DM1 SVF reveals a significant depletion
of ASCs in diabetic samples. **P ≤0.01.
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data). Given the proven efficacy of this hydrogel bioscaf-
fold, the negligible beneficial effect of traditionally isolated
diabetic ASCs when seeded in these constructs, particu-
larly in promoting in vivo neovascular processes following
ischemic injury, prompted us to explore the possibility of
differential cell enrichment as a potential means to restore
functionality.
Our recent work in the emerging field of microfluidic-
based single-cell gene expression analysis supports the
use of transcriptional-based cell clustering not only for
the characterization of cell phenotypes [18] but also as a
tool for functionality-based population enrichment [19].
Further justifying this approach, although others have
shown that diabetes can negatively impact the thera-
peutic potential of the heterogeneous SVF for wound-
healing applications [36], it remained unclear from this
work whether this deficiency was the result of a global
depletion of ASCs within the adipose tissue of diabetic
animals or alternatively the manifestation of a changing
membrane phenotype associated with impaired cell
functionality.
Casting a wide net in our surface marker-based defin-
ition of ASCs, we observed a depletion of putative ASCs(CD45−/CD31−/CD34+ cells) within the diabetic SVF,
which was consistent with the signaling dysfunction seen
in this environment. The presence of a global ASC deple-
tion does not exclude further phenotypic dysfunction,
however, and the microfluidic-based approach allowed us
to analyze the transcriptional profile of ASCs for pheno-
typic heterogeneity independent of a priori classifications.
Thus, the depletion of a putatively vasculogenic ASC sub-
population in diabetes identified here not only provides
further insight into the impaired phenotype of these cells
but also suggests that the regenerative effects of healthy
ASCs may be dependent upon a critical subpopulation of
cells. Based upon these findings, work is currently ongoing
to confirm the therapeutic efficacy of the identified sub-
population as well as to determine whether prospective
enrichment of the depleted diabetic ASC subpopulation
restores cell functionality.
Conclusions
The impaired therapeutic properties displayed by dia-
betic ASCs are likely related to the selective depletion of
a highly vasculogenic subpopulation of cells. Although
these data suggest that the utility of unaltered autolo-
gous ASCs for cell-based therapies in patients with
Figure 7 Single-cell transcriptional analysis of CD45−/CD31−/CD34+ ASCs. (A) Hierarchical clustering of cells from wild-type (WT; left),
db/db diabetic (DM2; middle), and STZ-induced diabetic (DM1; right) mice. Gene expression is presented as fold change from median on a color
scale from yellow (high expression, 32-fold above median) to blue (low expression, 32-fold below median). See Additional file 2: Figure S1 for
complete dataset. (B) Differentially expressed genes between wild-type (WT) and diabetic (db/db [DM2] or STZ [DM1]) cells identified by using
non-parametric two-sample Kolmogorov-Smirnov testing. Twenty-one genes exhibited significantly different (P <0.01 following Bonferroni correction
for multiple comparisons) distributions of single-cell expression between populations; six are illustrated here by using median-centered Gaussian curve
fits. The left bar for each panel represents the fraction of qPCR that failed to amplify in each group. Curves and p values for each gene are shown only
for those diabetic groups significantly different from wild-type cells. (C) wild-type, (D) DM2, and (E) DM1 cells based on the expression patterns of all
71 genes (k = 3). (F) Pie charts representing the fraction of ASCs comprising each cluster (WT [red], DM2 [green], and DM1 [blue]). (G) List of selected
cluster 3-defining genes.
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designed to enrich for depleted subpopulations are areas
of future study that may potentially improve diabetic
ASC function.Additional files
Additional file 1: Table S1. Gene names and assay IDs for microfluidic
single-cell gene expression analysis. Genes specifically relating to
stemness and vasculogenesis were chosen, in addition to selected
control, cell cycle, and surface marker-related probes.
Additional file 2: Figure S1. Whisker plots presenting raw quantitative
polymerase chain reaction (qPCR) cycle threshold (Ct) values for each
gene across all wild-type (WT) and diabetic adipose-derived mesenchymal
stem cells. Individual dots represent single gene/cell qPCR reactions, and
increased Ct values correspond to decreased mRNA content. Ct values of 40
were assigned to all reactions that failed to achieve detectable levels of
amplification within 40 qPCR cycles. Cells isolated from WT, db/db (DM2),
and STZ (DM1) diabetic mice are colored in red, green, and blue,
respectively. DM1, type 1 diabetes mellitus; DM2, type 2 diabetes mellitus.
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1-alpha; MMP: matrix metalloproteinase; Pdgf-a: platelet-derived growth
factor-A; qPCR: quantitative polymerase chain reaction; SVF: stromal vascular
fraction; Vegf: vascular endothelial cell growth factor; WT: wild-type.
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